DEF 14A: Definitive proxy statements
Published on April 29, 2009
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Securities Exchange Act of 1934
Filed by the Registrant þ | Filed by a party other than the Registrant o |
Check the appropriate box:
o Preliminary Proxy Statement
o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
þ Definitive Proxy Statement
o Definitive Additional Materials
o Soliciting Material under to §240.14a-12
o Preliminary Proxy Statement
o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
þ Definitive Proxy Statement
o Definitive Additional Materials
o Soliciting Material under to §240.14a-12
OPKO HEALTH, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ | No fee required | |
o | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11 |
(1) | Title of each class of securities to which transaction applies: | ||
(2) | Aggregate number of securities to which transaction applies: | ||
(3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | ||
(4) | Proposed maximum aggregate value of transaction: | ||
(5) | Total fee paid: |
o | Fee paid previously with preliminary materials. | |
o | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
(1) | Amount Previously Paid: | ||
(2) | Form, Schedule or Registration Statement No.: | ||
(3) | Filing Party: | ||
(4) | Date Filed: |
TABLE OF CONTENTS
Table of Contents
April 29, 2009
Dear Stockholder:
On behalf of the Board of Directors, I cordially invite you to attend the Annual Meeting of
Stockholders of OPKO Health, Inc. to be held at its headquarters at 4400 Biscayne Blvd., Miami,
Florida 33137, on Wednesday, June 10, 2009, beginning at 10:00 a.m. local time.
The attached Notice of Annual Meeting and Proxy Statement describe the matters expected to be
acted upon at the Annual Meeting. At the Annual Meeting, you will have an opportunity to meet
management and ask questions.
Whether or not you plan to attend the Annual Meeting, it is important that you vote your
shares. Regardless of the number of shares you own, please sign and date the enclosed proxy card
and promptly return it to us in the enclosed postage paid envelope. If you sign and return your
proxy card without specifying your choices, your shares will be voted in accordance with the
recommendations of the Board of Directors contained in the Proxy Statement.
We look forward to seeing you on June 10, 2009 and urge you to return your proxy card as soon
as possible.
Sincerely, | ||||
/s/ Phillip Frost | ||||
Phillip Frost | ||||
Chairman and Chief Executive Officer |
Table of Contents
OPKO HEALTH, INC.
4400 Biscayne Blvd.
Suite 1180
Miami, FL 33137
4400 Biscayne Blvd.
Suite 1180
Miami, FL 33137
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD JUNE 10, 2009
TO BE HELD JUNE 10, 2009
Notice is hereby given that the Annual Meeting of Stockholders (the Annual Meeting) of OPKO
Health, Inc., a Delaware corporation (the Company), will be held at the Companys headquarters at
4400 Biscayne Blvd., Miami, Florida, 33137, on Wednesday, June 10, 2009, beginning at 10:00 a.m.,
local time, for the following purposes:
1. To elect as directors the ten nominees named in the attached proxy statement for a term of
office expiring at the 2010 annual meeting of stockholders or until their respective successors are
duly elected and qualified; and
2. To transact such other business as may properly come before the Annual Meeting or any
adjournments thereof.
Only holders of record of our common stock, par value $0.01 per share, and our Series A
Preferred Stock, par value $0.01 per share, at the close of business on April 22, 2009, will be
entitled to notice of and to vote at the Annual Meeting or any adjournments thereof.
Whether or not you expect to be present, please sign and date the enclosed proxy and return it
in the postage paid, self-addressed envelope provided for your convenience. Management asks that
you do this whether or not you plan to attend the Annual Meeting. Should you attend, you may, if
you wish, withdraw your proxy and vote your shares in person.
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to Be Held on
June 10, 2009
June 10, 2009
The Proxy Statement and 2008 Annual Report are available at www.opko.com.
By Order of the Board of Directors, | ||||
/s/ Kate Inman | ||||
Kate Inman | ||||
Secretary |
Miami, Florida
April 29, 2009
April 29, 2009
Table of Contents
OPKO HEALTH, INC.
PROXY STATEMENT FOR THE 2009 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD
WEDNESDAY, JUNE 10, 2009
TO BE HELD
WEDNESDAY, JUNE 10, 2009
This proxy statement is furnished by the Board of Directors (Board) of OPKO Health, Inc.
(the Company or we, us or our) in connection with the solicitation of proxies to be voted
at the Annual Meeting of Stockholders of the Company that will be held at the Companys
headquarters at 4400 Biscayne Blvd., Miami, Florida 33137, on Wednesday, June 10, 2009, beginning
at 10:00 a.m., local time, and all adjournments thereof (the Annual Meeting), for the purposes
set forth in the accompanying Notice of Annual Meeting.
Our Board has fixed the close of business on April 22, 2009, as the record date for the
determination of stockholders entitled to notice of and to vote at the Annual Meeting or any
adjournments thereof. As of that date, there were issued and outstanding 200,749,392 shares of our
common stock, par value $0.01 per share, and 932,667 shares of our Series A Preferred Stock, par
value $0.01 per share. The holders of our common stock and Series A Preferred Stock are each
entitled to one vote for each outstanding share on all matters submitted to our stockholders. The
presence, in person or by proxy, of holders of a majority of our outstanding common and preferred
stock constitutes a quorum at the Annual Meeting. Shares of our stock represented by proxies that
reflect abstentions and broker non-votes (i.e., stock represented at the Annual Meeting by
proxies held by brokers or nominees as to which (i) the brokers or nominees have not received
instructions from the beneficial owners or persons entitled to vote and (ii) the broker or nominee
does not have the discretionary voting power on a particular matter) will be counted for the
purpose of determining the existence of a quorum at the Annual Meeting, but will not be counted as
a vote cast for or against any given matter.
Any stockholder giving a proxy will have the right to revoke it at any time prior to the time
it is voted. A proxy may be revoked by: (i) written notice to us at or prior to the Annual
Meeting, attention: Secretary; (ii) execution of a subsequent proxy; or (iii) attendance and voting
in person at the Annual Meeting. Attendance at the Annual Meeting will not automatically revoke
the proxy. All shares of our stock represented by effective proxies will be voted at the Annual
Meeting or at any adjournment thereof. Unless otherwise specified in the proxy, shares of our
stock represented by proxies will be voted: (i) FOR the election of the Boards nominees for
directors; and (ii) in the discretion of the proxy holders with respect to such other matters as
may properly come before the Annual Meeting.
Our executive offices are located at 4400 Biscayne Blvd., Suite 1180, Miami, Florida 33137.
Mailing to stockholders of record on April 22, 2009 of the Notice of Annual Meeting, this proxy
statement, the accompanying form of proxy and our Annual Report to Stockholders for our fiscal year
ended December 31, 2008 (fiscal 2008) will commence on or around April 30, 2009.
1
Table of Contents
Security Ownership of Certain Beneficial Owners
The following table contains information regarding the beneficial ownership of our common
stock as of April 15, 2009, held by (i) each stockholder known by us to beneficially own more than
5% of our common stock; (ii) our directors and nominees; (iii) our Named Executive Officers in 2008
as defined in the paragraph preceding the Summary Compensation Table and our current executive
officers; and (iv) all current directors and executive officers as a group. Except where noted,
all holders listed below have sole voting power and investment power over the shares beneficially
owned by them. Unless otherwise noted, the address of each person listed below is 4400 Biscayne
Blvd., Suite 1180, Miami, FL 33137.
Percentage of | ||||||||
Amount and Nature | Outstanding | |||||||
Name and Address of | Beneficial | Shares of Common | ||||||
Beneficial Owner | Ownership (1) | Stock** | ||||||
Frost Gamma Investments Trust |
125,917,744 | (2) | 53.4 | % | ||||
The Frost Group, LLC |
20,286,704 | (3) | 9.0 | % | ||||
Johnson & Johnson Development Corporation |
||||||||
One Johnson & Johnson Plaza |
||||||||
New Brunswick, NJ 08933 |
15,489,039 | (4) | 6.9 | % | ||||
Phillip Frost, M.D. |
||||||||
CEO & Chairman of the Board |
126,492,744 | (5) | 53.5 | % | ||||
Jane H. Hsiao, Ph.D., MBA |
||||||||
Vice Chairman of the Board & Chief Technical Officer |
24,359,111 | (6) | 10.9 | % | ||||
Steven D. Rubin |
||||||||
Executive Vice President Administration and Director |
5,525,608 | (7) | 2.5 | % | ||||
Rao Uppaluri, Ph.D. |
||||||||
Senior Vice President and Chief Financial Officer |
5,177,689 | (8) | 2.3 | % | ||||
Naveed K. Shams, M.D., Ph.D. |
||||||||
Senior Vice President Research and Development and Chief |
||||||||
Medical Officer |
43,700 | (9) | * | |||||
Robert Baron, Director |
348,000 | (10) | * | |||||
John A. Paganelli, Director |
310,000 | (11) | * | |||||
Richard A. Lerner, M.D., Director |
40,000 | (12) | * | |||||
Pascal J. Goldschmidt, M.D., Director |
40,000 | (13) | * | |||||
Richard C. Pfenniger, Jr., Director |
90,000 | (14) | * | |||||
Thomas E. Beier, Director |
140,000 | (15) | * | |||||
Alice Lin-Tsing Yu, M.D., Ph.D., Director |
0 | * | ||||||
All Executive Officers and Directors as a group (12 persons) |
162,566,852 | 67.0 | % |
* | Less than 1% | |
** | Percentages based upon 220,694,392 shares of our common stock issued and outstanding at April 15, 2009. The total outstanding shares includes 20,000,000 shares of our common stock to be issued in connection with a stock purchase agreement between the Company and Frost Gamma Investments Trust, dated February 23, 2009. | |
(1) | All shares beneficially owned represent shares of common stock unless otherwise indicated. | |
(2) | Includes warrants to purchase 10,201,093 shares of common stock. Also includes 15,490,546 shares of common stock and warrants to purchase 4,796,158 shares of common stock held by The Frost Group, LLC, of which Frost Gamma Investments Trust is a principal member. Frost Gamma Investments Trust disclaims beneficial ownership of the common stock and warrants held by The Frost Group, LLC, except to the extent of its pecuniary interest therein. | |
(3) | Includes warrants to purchase 4,796,158 shares of common stock. | |
(4) | Includes warrants to purchase 2,949,142 shares of common stock and options to purchase 295,797 shares of common stock. | |
(5) | Includes 95,429,947 shares of common stock and warrants to purchase 10,201,093 shares of common stock held by Frost Gamma Investments Trust. It also includes options to purchase 575,000 shares of common stock by Dr. Frost. Dr. Frost is the trustee and Frost Gamma, Limited Partnership is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma, Limited Partnership. The general partner of Frost Gamma, Limited Partnership is Frost Gamma Inc. and the |
2
Table of Contents
sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole stockholder of Frost-Nevada Corporation. The number of shares included above also includes 15,490,546 shares of common stock and warrants to purchase 4,796,158 shares of common stock owned directly by The Frost Group, LLC. Frost Gamma Investments Trust is a principal member of The Frost Group, LLC. Dr. Frost and the Frost Gamma Investments Trust disclaim beneficial ownership of these shares of common stock and warrants to purchase common stock, except to the extent of any pecuniary interest therein. | ||
(6) | Includes warrants to purchase 2,936,580 shares of common stock and options to purchase 387,500 shares of common stock. It also includes 1,000,000 shares of common stock held by each of The Chiin Hsiung Hsiao Family Trust A and The Chiin Hsiung Hsiao Family Trust B, for which Dr. Hsiao serves as the sole trustee of both, and 2,354,800 shares of common stock held by Hsu Gamma Investment, L.P, for which Dr. Hsiao serves as General Partner. Dr. Hsiao is a member of the Frost Group, LLC, which holds 15,490,546 shares of common stock and warrants to purchase 4,796,158 shares of common stock. Dr. Hsiao disclaims beneficial ownership of the shares of common stock and warrants held by The Frost Group, LLC, except to the extent of any pecuniary interest therein. | |
(7) | Includes warrants to purchase 1,036,440 shares of common stock and options to purchase 300,000 shares of common stock. Mr. Rubin is a member of the Frost Group, LLC, which holds 15,490,546 shares of common stock and warrants to purchase 4,796,158 shares of common stock. Mr. Rubin disclaims beneficial ownership of the shares of common stock and warrants held by The Frost Group, LLC, except to the extent of any pecuniary interest therein. | |
(8) | Includes warrants to purchase 950,070 shares of common stock and options to purchase 243,750 shares of common stock. It also includes 161,000 shares held directly by Dr. Uppaluris wife. Dr. Uppaluri is a member of the Frost Group, LLC, which holds 15,490,546 shares of common stock and warrants to purchase 4,796,158 shares of common stock. Dr. Uppaluri disclaims beneficial ownership of the shares of common stock and warrants held by The Frost Group, LLC, except to the extent of any pecuniary interest therein. Dr. Uppaluri also disclaims ownership of 161,000 shares held by his wife. | |
(9) | Includes options to acquire 37,500 shares of common stock. | |
(10) | Includes options to acquire 95,000 shares of common stock. | |
(11) | Includes options to acquire 95,000 shares of common stock. | |
(12) | Includes options to acquire 40,000 shares of common stock. | |
(13) | Includes options to acquire 40,000 shares of common stock. | |
(14) | Includes options to acquire 40,000 shares of common stock. | |
(15) | Includes options to acquire 40,000 shares of common stock. |
3
Table of Contents
PROPOSAL ONE:
ELECTION OF DIRECTORS
Nominees for Election of Directors
Pursuant to the power granted to our Board of Directors under Article III of our Amended and
Restated Bylaws, the Board has fixed the number of directors constituting the entire Board at ten.
All ten directors are to be elected at the Annual Meeting, each to hold office until the 2010
annual meeting of stockholders and until his successor is duly elected and qualified. Each
stockholder of record on April 22, 2009 is entitled to cast one vote for each share of our common
stock and Series A Preferred Stock held of record, either in favor of or against the election of
each nominee, or to abstain from voting on any or all nominees. All shares of our common stock and
Series A Preferred Stock vote together as a single class. Although management does not anticipate
that any nominee will be unable or unwilling to serve as director, in the event of such an
occurrence, proxies may be voted in the discretion of the persons named in the proxy for a
substitute designated by the Board, unless the Board decides to reduce the number of directors
constituting the Board. Each nominee shall be elected if the votes cast in favor of a nominee by
the holders of shares of our common stock and Series A Preferred Stock present or represented and
entitled to vote at the Annual Meeting at which a quorum is present, exceed the votes cast against
a nominee.
The following sets forth information provided by the nominees as of April 15, 2009, all of
whom are currently serving as directors of the Company and all of whom have consented to serve if
reelected by our stockholders.
Year First | ||||||||||
Elected/ | ||||||||||
Nominated | ||||||||||
Name of Nominee | Age | Director | Positions and Offices with the Company | |||||||
Phillip Frost, M.D.
|
72 | 2007 | Chairman of the Board and Chief Executive Officer | |||||||
Jane H. Hsiao, Ph.D.
|
61 | 2007 | Vice Chairman of the Board and Chief Technical Officer | |||||||
Steven D. Rubin
|
48 | 2007 | Director and Executive Vice President-Administration | |||||||
Robert A. Baron
|
69 | 2003 | Director | |||||||
Thomas E. Beier
|
63 | 2008 | Director | |||||||
Pascal J. Goldschmidt, M.D.
|
55 | 2007 | Director | |||||||
Richard A. Lerner, M.D.
|
70 | 2007 | Director | |||||||
John A. Paganelli
|
74 | 2003 | Director | |||||||
Richard C. Pfenniger, Jr.
|
53 | 2008 | Director | |||||||
Alice Lin-Tsing Yu, M.D., Ph.D.
|
65 | 2009 | Director |
Phillip Frost, M.D. Dr. Frost became the CEO and Chairman of OPKO Health, Inc. upon the
consummation of the merger of Acuity Pharmaceuticals Inc., Froptix Corporation and eXegenics, Inc.
on March 27, 2007 (referred to as the Acquisition). Dr. Frost was named the Vice Chairman of the
Board of Teva Pharmaceutical Industries, Limited (NasdaqGS:TEVA), or Teva, in January 2006 when Teva acquired IVAX
Corporation, or IVAX. Dr. Frost had served as Chairman of the Board of Directors and Chief
Executive Officer of IVAX Corporation since 1987. He was Chairman of the Department of Dermatology
at Mt. Sinai Medical Center of Greater Miami, Miami Beach, Florida from 1972 to 1986. Dr. Frost
was Chairman of the Board of Directors of Key Pharmaceuticals, Inc. from 1972 until the acquisition
of Key Pharmaceuticals by Schering Plough Corporation in 1986. Dr. Frost was named Chairman of the
Board of Ladenburg Thalmann Financial Services Inc. (NYSE Amex: LTS), an investment banking, asset
management, and securities brokerage firm providing services through its principal operating
subsidiary, Ladenburg Thalmann & Co. Inc., in July 2006 and has been a director of Ladenburg
Thalmann since March 2005. Dr. Frost also serves as Chairman of the Board of Directors of Ideation
Acquisition Corp., a special purpose acquisition company formed for the purpose of acquiring
businesses in digital media (NYSE Amex: IDI), Modigene Inc., a development stage biopharmaceutical
company (OTCBB: MODG), and Castle Brands, a developer and marketer of premium brand spirits (NYSE
Amex: ROX). He serves on the Board of Regents of the Smithsonian Institution, as a member of the
Board of Trustees of the University of Miami, a Trustee of each of the Scripps Research Institutes,
the Miami Jewish Home for the Aged, and the Mount Sinai Medical Center. Dr. Frost is also a
director of Continucare Corporation, a provider of outpatient healthcare and home healthcare
services (NYSE Amex: CNU), and Northrop Grumman Corp., a global defense and aerospace company
(NYSE: NOC).
4
Table of Contents
Jane H. Hsiao, Ph.D., MBA. Dr. Hsiao has served as Vice-Chairman and Chief Technical Officer
of the Company since May 2007. Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX
from 1995 to January 2006, when Teva acquired IVAX. Dr. Hsiao served as IVAXs Chief Technical
Officer since 1996, and as Chairman, Chief Executive Officer and President of IVAX Animal Health,
IVAXs veterinary products subsidiary, since 1998. From 1992 until 1995, Dr. Hsiao served as
IVAXs Chief Regulatory Officer and Assistant to the Chairman. Dr. Hsiao has served as Chairman of
the Board of each of Safestitch Medical, Inc. (OTCBB: SFES) and Non-Invasive Monitoring Systems,
Inc. (OTCBB: NIMU), both medical device companies, since September 2007 and October 2008,
respectively. Dr. Hsiao is also a director of Modigene, Inc., a development stage
biopharmaceutical company (OTCBB: MODG) and Neovasc, Inc., a company developing and
marketing medical specialty vascular devices (TSXV:NVC).
Steven D. Rubin. Mr. Rubin has served as Executive Vice President Administration since May
2007 and a director of the Company since February 2007. Mr. Rubin served as the Senior Vice
President, General Counsel and Secretary of IVAX from August 2001 until September 2006. Prior to
joining IVAX, Mr. Rubin was Senior Vice President, General Counsel and Secretary with
privately-held Telergy, Inc., a provider of business telecommunications and diverse optical network
solutions, from early 2000 to August 2001. In addition, he was with the Miami law firm of Stearns
Weaver Miller Weissler Alhadeff & Sitterson from 1986 to 2000, in the Corporate and Securities
Department. Mr. Rubin had been a shareholder of that firm since 1991 and a director since 1998.
Mr. Rubin currently serves on the board of directors of Dreams, Inc., a vertically integrated
sports licensing and products company (NYSE Amex: DRJ), Safestitch Medical, Inc., a medical device
company (OTCBB: SFES), Modigene, Inc., a development stage biopharmaceutical company (OTCBB:
MODG), Kidville, Inc., which operates large, upscale facilities, catering to newborns through
five-year-old children and their families and offers a wide range of developmental classes for
newborns to 5 year olds (OTCBB:KVIL), Non-Invasive Monitoring Systems, Inc., a medical device
company (OTCBB: NIMU), Cardo Medical, Inc., an early-stage orthopedic medical device company
specializing in designing, developing and marketing reconstructive joint devices and spinal
surgical devices (OTCBB:CDOM), Castle Brands, Inc., a developer and marketer of premium brand
spirits (NYSE Amex: ROX), and Neovasc, Inc., a company developing and marketing medical specialty
vascular devices (TSXV:NVC).
Robert A. Baron. Mr. Baron has served as a director of the Company since 2003. Mr. Baron is
currently a director of Hemobiotech, Inc. (OTCBB:HMBT), a development stage biopharmaceutical
company, Andover Medical, Inc., a durable medical equipment distributor (OTCBB:ADOV), and
Nanosensors, Inc., an internet gaming business (OTCBB:NNSR). Prior to that he was president of
Cash City, Inc., a payday advance and check cashing business, from 1999 to 2003. From 1997 to
1999, Mr. Baron was the president of East coast operations for CSS/TSC, Inc., a distributor of
blank t-shirts, fleece and accessories and a subsidiary of Tultex, Inc.
Thomas E. Beier. Mr. Beier has served as a director of the Company since January 2008.
Previously, he was Senior Vice President of Finance and Chief Financial Officer of IVAX Corporation
from October 1997 until August 2007, and from December 1996 until October 1997, he served as Vice
President-Finance for IVAX. Before joining IVAX, Mr. Beier served as Executive Vice President and
Chief Financial Officer of Intercontinental Bank. Mr. Beier currently is a director of Ideation
Acquisition Corp., a special purpose acquisition company formed for the purpose of acquiring
businesses in digital media (NYSE Amex: IDI).
Pascal J. Goldschmidt, M.D. Dr. Goldschmidt has served as a director of the Company since
September 2007. Since April 2006, Dr. Goldschmidt has served as Senior Vice President for Medical
Affairs and Dean of the University of Miami Leonard M. Miller School of Medicine. Previously Dr.
Goldschmidt was a faculty member with the Department of Medicine at Duke University Medical Center,
where he served as Chairman from 2003 to 2006 and as Chief of the Division of Cardiology from 2000
to 2003. Dr. Goldschmidt is a member of the Board of Directors of Pediatrix Medical Group, Inc.
(NYSE: PDX).
Richard A. Lerner, M.D. Dr. Lerner has served as a director of the Company since March 2007.
Dr. Lerner has been President of The Scripps Research Institute, a private, non-profit biomedical
research organization, since 1986. Dr. Lerner is a member of numerous scientific associations,
including the National Academy of Science and the Royal Swedish Academy of Sciences. Dr. Lerner
serves as director of Kraft Foods, Inc. (NYSE:KFT). He is also on the Board of Directors for
Xencor and Intra-Cellular Therapies, two privately held biotechnology companies, and serves on the
Siemens Advisory Board for Molecular Medicine of Siemens AG.
5
Table of Contents
John A. Paganelli. Mr. Paganelli has served as a Director of the Company since December 2003.
Mr. Paganelli served as the Companys Interim Chief Executive Officer and secretary from June 29,
2005 through March 27, 2007, and Chairman of our Board of Directors from December 2003 through
March 27, 2007. Mr. Paganelli served as President and Chief Executive Officer of Transamerica Life
Insurance Company of New York from 1992 to 1997. Since 1987, Mr. Paganelli has been a partner in
RFG Associates, a financial planning organization. Mr. Paganelli is also the Managing Partner of
Pharos Systems Partners, LLC, an investment company, and he is Chairman of the Board of Pharos
Systems International. He was Vice President and Executive Vice President of PEG Capital
Management, an investment advisory organization, from 1987 until 2000. From 1980 to January 2003,
Mr. Paganelli was an officer and director-shareholder of Mike Barnard Chevrolet, Inc., an
automobile dealership.
Richard C. Pfenniger, Jr. Mr. Pfenniger has served as a director of the Company since January
2008. Mr. Pfenniger has served as Chief Executive Officer and President for Continucare
Corporation (NYSE Amex:CNU), a provider of primary care physician and practice management services,
since October 2003, and as Chairman of the Board of Directors of Continucare since September 2002.
Previously, Mr. Pfenniger served as the Chief Executive Officer and Vice Chairman of Whitman
Education Group, Inc. from 1997 through June 2003. Prior to joining Whitman, he served as the
Chief Operating Officer of IVAX from 1994 to 1997, and, from 1989 to 1994, he served as the Senior
Vice President-Legal Affairs and General Counsel of IVAX Corporation. Mr. Pfenniger currently
serves as a director of GP Strategies Corporation, a corporate education and training company
(NYSE:GPX), and SafeStitch Medical, Inc., a medical device company (OTCBB:SFES).
Alice Lin-Tsing Yu, M.D., Ph.D. Dr. Yu was appointed to the Companys board of directors in
April 2009. Since 2003, Dr. Yu has served as Distinguished Research Fellow and Associate Director
at the Genomics Research Center, Academia Sinica, in Taiwan. She has also served as a Professor of
Pediatrics for both the National Taiwan University and University of California in San Diego, since
2004 and 1994, respectively. Previously, she was the Chief of Pediatric Hematology Oncology at the
University of California in San Diego. Dr. Yu has also served in several government-appointed
positions and is a member of numerous scientific committees and associations.
OUR BOARD RECOMMENDS A VOTE FOR THE ELECTION OF ALL NOMINEES NAMED ABOVE.
Identification of Executive Officers
Set forth below is the name and age as of April 15, 2009 of each of our current executive
officers, together with certain biographical information for each of them (other than Phillip
Frost, Jane H. Hsiao, and Steven Rubin, for whom biographical information is included above under
Nominees for Election of Directors):
Name of Executive Officer | Age | Position and Offices with the Company | ||
Rao Uppaluri, Ph.D.
|
59 | Senior Vice President and Chief Financial Officer | ||
Naveed K. Shams, M.D., Ph.D.
|
52 | Senior Vice President Research and Development and Chief Medical Officer |
Rao Uppaluri, Ph.D. Dr. Uppaluri has served as our Senior Vice President and Chief Financial
Officer since May 2007. Dr. Uppaluri served as the Vice President, Strategic Planning and
Treasurer of IVAX from 1997 until December 2006. Before joining IVAX, from 1987 to August 1996,
Dr. Uppaluri was Senior Vice President, Senior Financial Officer and Chief Investment Officer with
Intercontinental Bank, a publicly traded commercial bank in Florida. In addition, he served in
various positions, including Senior Vice President, Chief Investment Officer and Controller, at
Peninsula Federal Savings & Loan Association, a publicly traded Florida S&L, from October 1983 to
1987. His prior employment, during 1974 to 1983, included engineering, marketing and research
positions with multinational companies and research institutes in India and the United States. Dr.
Uppaluri currently serves on the board of directors of Ideation Acquisition Corp., a special
purpose acquisition company formed for the purpose of acquiring businesses in digital media (NYSE Amex:IDI),
Kidville, Inc , which operates large, upscale facilities, catering to newborns through
five-year-old children and their families and offers a wide range of developmental classes for
newborns to 5 year olds (OTCBB:KVIL), Cardo Medical, Inc., an early-stage orthopedic medical device company
specializing in designing, developing and marketing reconstructive joint devices and spinal
surgical devices (OTCBB:CDOM), Non-Invasive Monitoring Systems, Inc., a medical devices company (OTCBB:NIMU), and Winston
Pharmaceuticals Inc., a specialty pharmaceutical company engaged in the discovery and
development of products for pain management (OTCBB:WPHM).
6
Table of Contents
Naveed Shams, M.D., Ph.D. Dr. Shams has served as the Companys Chief Medical Officer and
Senior Vice President of Research and Development since January 2008. Prior to joining the
Company, Dr. Shams served from September 2003 through November 2007 as Senior Medical Director,
Head Ophthalmic Medical Affairs and Post-Marketing Team Leader at Genentech, Inc., a pharmaceutical
company, where he led the clinical team responsible for launching Lucentis®. Previously, Dr. Shams
was also a Director, Clinical Science for Novartis Ophthalmics, Inc. from April 1998 through
September 2003, and Senior Scientist and Glaucoma Group Leader-Discovery for Storz Ophthalmics from
January 1995 through March 1998. Before joining industry, Dr. Shams was a member of the Research
Faculty at the Schepens Eye Research Institute and Department of Ophthalmology at Harvard Medical
School.
7
Table of Contents
CORPORATE GOVERNANCE
Our common stock is listed on the NYSE Amex Exchange (NYSE Amex). Pursuant to the Companys
Amended and Restated Bylaws and the Delaware General Corporation Law, our business and affairs are
managed under the direction of our Board of Directors. Directors are kept informed of the
Companys business through discussions with management, including our Chief Executive Officer,
Chief Financial Officer, and other senior officers, by reviewing materials provided to them and by
participating in meetings of the Board of Directors and its committees. The Company has adopted a
Code of Business Conduct and Ethics that applies to all employees, officers, and directors of the
Company. The Code of Business Conduct and Ethics is available on our website: www.opko.com under
Investor Relations. If the Company makes any substantive amendments to, or grants a waiver
(including an implicit waiver) from, a provision of our Code of Business Conduct and Ethics that
applies to our principal executive officer, principal financial officer, principal accounting
officer or controller, and that relates to any element of the code of ethics definition enumerated
in Item 406(b) of Regulation S-K, promulgated under the Securities Exchange Act of 1934, as amended
(the Exchange Act), we will disclose such amendment or waiver on our website.
Controlled Company
Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frost, our Chairman and Chief
Executive Officer, beneficially owns in excess of 50% of our issued and outstanding common stock.
As a result, the Company may be deemed to be a controlled company under the NYSE Amex Company
Guide and, therefore, would not be subject to NYSE Amexs rules otherwise requiring companies
listed thereon to have a Board of Directors consisting of at least a majority of independent
directors, governing the determination of executive compensation and governing the nomination of
directors. The Company intends, however, to continue to comply with NYSE Amexs minimum
independent director rules, executive compensation determination rules, and director nomination
rules.
Director Independence
In evaluating the independence of each of our directors, the Board of Directors considers
transactions and relationships between each director or any member of his or her immediate family
and the Company and its subsidiaries and affiliates. The Board of Directors also examined
transactions and relationships between directors or their known affiliates and members of the
Companys senior management and their known affiliates. The purpose of this review is to determine
whether any such relationships or transactions are inconsistent with a determination that the
director is independent under applicable laws and regulations and NYSE Amex listing standards. The
Board of Directors affirmatively determined that a majority of our directors, including Messrs.
Robert A. Baron, Thomas E. Beier, Richard C. Pfenniger, Jr., and Drs. Pascal J. Goldschmidt,
Richard A. Lerner and Alice Lin-Tsing Yu, are independent directors within the meaning of the
listing standards of NYSE Amex and applicable law. In making the independence determinations, the
Board considered a number of factors and relationships, including (i) Dr. Frosts service as a
member of the Board of Trustees for the University of Miami and its Service Committee, a 501(c)(3)
entity for which Dr. Goldschmidt serves as an executive officer; and (ii) Dr. Frosts service on
the board of directors for Continucare Corporation, an entity for which Mr. Pfenniger serves as
Chairman, Chief Executive Officer, and President. Dr. Frost abstains from participating in any
Service Committee or Board of Trustee decisions which may implicate Dr. Goldschmidts compensation.
As required by the NYSE Amex, the Companys independent directors meet at least annually in
executive session without the presence of its non-independent directors or management.
Board of Directors Voting
We currently have ten directors comprising the entirety of our Board. The Frost Group, LLC
(the Frost Group), an entity controlled by our Chairman and CEO and several of our members of
senior management, has agreed to vote for two of the directors, Messrs. Paganelli and Baron, under
the Board of Director composition provisions of a voting agreement between the Frost Group and the
Company. In addition, three of our current directors, Drs. Frost and Hsiao and Mr. Rubin, were
elected to the Board pursuant to the merger agreement entered into in connection with the
Acquisition.
8
Table of Contents
Meetings and Committees of the Board of Directors
Our Board met eight times during fiscal 2008. We intend for the independent directors of the
Board to meet separately from Board meetings from time to time at their discretion. In fiscal
2008, all incumbent directors attended 75% or more of the Board meetings and meetings of the
committees on which they served.
Although we encourage each member of our Board of Directors to attend our annual meetings of
stockholders, we do not have a formal policy requiring the members of our Board of Directors to
attend. Seven members of our Board of Directors attended the annual meeting of stockholders during
fiscal 2008.
Standing Committees of the Board of Directors
Our Board of Directors maintains several standing committees, including a compensation
committee, a nominating and governance committee, and a separately designated standing audit
committee established in accordance with Section 3(a)(58)(A) of the Exchange Act, and the rules and
regulations promulgated thereunder. These committees and their functions are described below. Our
Board of Directors may also establish various other committees to assist it in its
responsibilities. Our Board of Directors has adopted a written charter for each of its standing
committees. The full text of each charter is available on our website at http://www.opko.com.
The following table shows the current members (indicated by an X or Chair) of each of our
standing Board committees:
Corporate | ||||||||||||
Governance | ||||||||||||
and | ||||||||||||
Audit | Compensation | Nominating | ||||||||||
Phillip Frost, M.D. |
| | | |||||||||
Jane H. Hsiao, Ph.D., MBA |
| | | |||||||||
Robert A. Baron |
X | | Chair | |||||||||
Thomas E. Beier |
X | X | | |||||||||
Pascal J. Goldschmidt, M.D. |
| X | X | |||||||||
Richard A. Lerner, M.D. |
| Chair | X | |||||||||
John A. Paganelli |
| | | |||||||||
Richard C. Pfenniger, Jr. |
Chair | | | |||||||||
Steven D. Rubin |
| | | |||||||||
Alice Lin-Tsing Yu, M.D., Ph.D. |
| | |
Audit Committee
Our audit committee oversees our corporate accounting and financial reporting process. Our
audit committee met nine times during fiscal 2008. The responsibilities of our audit committee are
set forth in a written charter adopted by our Board of Directors and reviewed and reassessed
annually by the audit committee. Our audit committee:
| evaluates the qualifications, independence and performance of our independent registered public accounting firm; | ||
| determines the engagement of our independent registered public accounting firm; | ||
| approves the retention of our independent registered public accounting firm to perform any proposed permissible non-audit services; | ||
| reviews our systems of internal controls established for finance, accounting, legal compliance, and ethics; | ||
| reviews our accounting and financial reporting processes; | ||
| provides for effective communication between our Board of Directors, our senior and financial management, and our independent auditors; |
9
Table of Contents
| discusses with management and our independent auditors the results of our annual audit and the review of our quarterly financial statements; | ||
| reviews the audits of our financial statements; | ||
| implements a pre-approval policy for certain audit and non-audit services performed by our registered independent public accounting firm; and | ||
| reviews and approves any related party transactions that we are involved in. |
Our audit committee is composed of Messrs. Pfenniger, Baron, and Beier. Our Board of
Directors has determined that Messrs. Pfenniger and Beier, each of whom is independent as
independence for audit committee members is defined in NYSE Amex listing standards, is an audit
committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-K.
Compensation Committee
Our compensation committee reviews and either approves, on behalf of the Board of Directors,
or recommends to the Board of Directors for approval, (i) annual salaries, bonuses, and other
compensation for our executive officers, and (ii) individual equity awards for our employees and
executive officers. Our compensation committee also oversees our compensation policies and
practices. Our compensation committee met four times during fiscal 2008. Our compensation
committee may from time to time establish a subcommittee to perform any action required to be
performed by a committee of non-employee directors pursuant to Rule 16b-3 under the Securities
Exchange Act of 1934 and outside directors pursuant to Rule 162(m) under the Internal Revenue
Code.
Our compensation committee also performs the following functions related to executive
compensation:
| reviews and approves the annual salary, bonus, stock options, and other benefits, direct and indirect, of our executive officers, including our Chief Executive Officer; | ||
| reviews and recommends new executive compensation programs; reviews the operation and efficacy of our executive compensation programs; | ||
| establishes and periodically reviews policies in the area of senior management perquisites; | ||
| reviews and approves material changes in our employee benefit plans; | ||
| administers our equity compensation and employee stock purchase plans; and | ||
| reviews the adequacy of the compensation committee charter and recommends any proposed changes to the Board of Directors not less than annually. |
In deciding upon the appropriate level of compensation for our executive officers, the
compensation committee reviews our compensation programs relative to our strategic objectives and
market practice and other changing business and market conditions. In addition, the compensation
committee also takes into consideration the recommendations of our Chief Executive Officer
concerning compensation actions for our other executive officers and may engage compensation
consultants if the committee deems it appropriate.
Our compensation committee is composed of Dr. Lerner (Chairman), Dr. Goldschmidt, and Mr.
Beier. We believe that the composition and functioning of our compensation committee complies with
all applicable requirements of the Sarbanes-Oxley Act of 2002, the NYSE Amex, and the SECs rules
and regulations, including those regarding the independence of our compensation committee members.
Compensation Committee Interlocks and Insider Participation
The current members of our compensation committee are Dr. Lerner, Mr. Beier, and Dr.
Goldschmidt. None of these individuals was at any time during fiscal 2008 or at any time prior
thereto, an officer or employee of ours.
10
Table of Contents
Corporate Governance and Nominating Committee
Our corporate governance and nominating committees responsibilities include the selection of
potential candidates for our Board of Directors, making recommendations to our Board of Directors
concerning the structure and membership of the other Board committees, and considering director
candidates recommended by others, including our Chief Executive Officer, other Board members, third
parties, and stockholders. Our corporate governance and nominating committee is composed of Mr.
Baron (Chairman), Dr. Goldschmidt, and Dr. Lerner. Our corporate governance and nominating
committee met one time during fiscal 2008 and took action by written consent on two occasions. We
believe that the composition of our corporate governance and nominating committee complies with
applicable requirements of the Sarbanes-Oxley Act of 2002, the NYSE Amex, and SECs rules and
regulations, including those regarding the independence of our corporate governance and nominating
committee members.
The corporate governance and nominating committee identifies director nominees through a
combination of referrals, including by stockholders, existing members of the Board of Directors,
management, third parties, and direct solicitations, where warranted. Once a candidate has been
identified, the corporate governance and nominating committee reviews the individuals experience
and background, and may discuss the proposed nominee with the source of the recommendation. The
corporate governance and nominating committee usually believes it to be appropriate for committee
members to interview the proposed nominee before making a final determination whether to recommend
the individual as a nominee to the entire Board of Directors to stand for election to the Board of
Directors. The committee does not plan to evaluate candidates identified by the corporate
governance and nominating committee differently from those recommended by a stockholder or
otherwise.
The corporate governance and nominating committee has met and determined to recommend to the
Board that it nominate each of the incumbent directors for election at the Annual Meeting.
Director Selection Criteria
The corporate governance and nominating committee reviews and makes recommendations to the
Board of Directors regarding the appropriate qualifications, skills, and experience expected of
individual members and of the Board of Directors as a whole with the objective of having a Board of
Directors with sound judgment and diverse backgrounds and experience to represent stockholder
interests.
The corporate governance and nominating committee believes that nominees for election to the
Board of Directors should possess sufficient business or financial experience and a willingness to
devote the time and effort necessary to discharge the responsibilities of a director. This
experience can include, but is not limited to, service on other boards of directors or active
involvement with other boards of directors, experience in the industries in which the Company
conducts its business, audit and financial expertise, clinical experience, operational experience,
or a scientific or medical background. The corporate governance and nominating committee does not
believe that nominees for election to the Board of Directors should be selected through mechanical
application of specified criteria. Rather, the corporate governance and nominating committee
believes that the qualifications and strengths of individuals should be considered in their
totality with a view to nominating persons for election to the Board of Directors whose
backgrounds, integrity, and personal characteristics indicate that they will make a positive
contribution to the Board of Directors.
Stockholder Nominations
The corporate governance and nominating committee will consider director candidates
recommended by stockholders. Stockholders who wish to recommend candidates for election to the
Board of Directors must do so in writing. The recommendation should be sent to the Secretary of
the Company, OPKO Health, Inc., 4400 Biscayne Boulevard, Miami, Florida 33137, who will forward the
recommendation to the corporate governance and nominating committee. The recommendation must set
forth (i) the name and address as they appear on the Companys books of the stockholder making the
recommendation and the class and number of shares of capital stock of the Company beneficially
owned by such stockholder and (ii) the name of the candidate and all information relating to the
candidate that is required to be disclosed in solicitations of proxies for election of directors
under the SECs proxy rules. The recommendation must be accompanied by the candidates written
consent to being named in the Companys proxy statement as a nominee for election to the Board of
Directors and to serving as a director, if
11
Table of Contents
elected. Stockholders must also comply with all requirements of the Companys Amended and
Restated Bylaws with respect to nomination of persons for election to the Board of Directors.
Stockholder Communications with the Board
Stockholders may initiate in writing any communication with our Board of Directors or any
individual director by sending the correspondence to OPKO Health, Inc., 4400 Biscayne Blvd., Miami,
Florida 33137, Attention: Secretary. This centralized process assists our Board of Directors in
reviewing and responding to stockholder communications in an appropriate manner. If a stockholder
would like the letter to be forwarded directly to one of the Chairmen of the three standing
committees of the Board, he or she should so indicate. If no specific direction is indicated, the
Secretarys office will review the letter and forward it to the appropriate Board member(s).
Employee Communications with the Audit Committee
The audit committee has established procedures for the receipt, retention, and treatment of
complaints regarding accounting, internal accounting controls or auditing matters, and the
confidential, anonymous submission by employees of concerns regarding questionable accounting and
auditing matters. These procedures are described in our OPKO Health, Inc. Policy for Reporting
Questionable Accounting and Auditing Practices and Policy Prohibiting Retaliation Against Reporting
Employees.
Certain Relationships and Related Party Transactions
Frost Gamma Investments Trust (the Gamma Trust), a trust controlled by Dr. Phillip Frost,
our Chairman of the Board and Chief Executive Officer, Jane H. Hsiao, our Vice Chairman and Chief
Technical Officer, Steven D. Rubin, our Executive Vice President Administration and a member of
our Board of Directors, and Rao Uppaluri, our Senior Vice President and Chief Financial Officer,
are members of The Frost Group, LLC, or the Frost Group, an entity which beneficially owns
approximately 9% of our common stock. Furthermore, the Gamma Trust beneficially owns approximately
53.4% of our common stock.
On February 9, 2007, the Frost Group entered into a voting agreement with us pursuant to which
the Frost Group agreed to vote its shares of our common stock for the election of John Paganelli
and Robert Baron as directors. The voting agreement continues for a period of three years. In
addition, three of our current directors, Drs. Frost and Hsiao and Mr. Rubin, were elected to the
Board pursuant to the merger agreement entered into in connection with the Acquisition.
We currently have a fully utilized $12.0 million line of credit with the Frost Group. In
connection with the line of credit, we issued 4,000,000 warrants to the Frost Group in 2007. We
are obligated to pay interest upon maturity, capitalized quarterly, on outstanding borrowings under
the line of credit at a 10% annual rate, which is due July 11, 2009. The line of credit is
collateralized by all of our personal property except our intellectual property. Effective
November 6, 2008, the maturity date on the line of credit was extended for a period of eighteen
months from July 11, 2009 until January 11, 2011, and the annual interest rate was increased to 11%
from the amendment date forward.
In June 2007, we paid the $125,000 filing fee to the Federal Trade Commission (the FTC) in
connection with filings made by us and Dr. Frost, our Chairman and Chief Executive Officer, under
the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act). In March 2009, we also paid
a $45,000 filing fee to the FTC in connection with another filing made by us and Dr. Frost under
the HSR Act. The filings permitted Dr. Frost and his affiliates to acquire additional shares of
our common stock upon expiration of the HSR waiting period on July 12, 2007 and March 23, 2009,
respectively.
In November 2007, we entered into an office lease with Frost Real Estate Holdings, LLC, an
entity affiliated with Dr. Frost, the Companys Chairman of the Board and Chief Executive Officer.
The lease is for approximately 8,300 square feet of space in an office building in Miami, Florida,
where the Companys principal executive offices are located. The lease provides for payments of
approximately $18,000 per month in the first year increasing annually to $24,000 per month in the
fifth year, plus applicable sales tax. The rent is inclusive of operating expenses, property taxes
and parking. The rent for the first year was reduced to reflect a $30,000 credit for the costs of
tenant improvements. As of January 1, 2008, we began leasing an additional 1,100 square feet of
general office
12
Table of Contents
and laboratory space on a ground floor annex of our corporate office building pursuant to an
addendum to the lease, which required us to pay annual rent of $19,872 per year for the annex
space, subject to annual increases. Effective October 1, 2008, we terminated this addendum and are
no longer leasing this annex space.
On December 5, 2007, we issued 10,869,565 shares of the our common stock, par value $.01, to
members of the Frost Group in exchange for a $20 million cash investment, or $1.84 per share,
representing an approximately 40% discount to the average trading price of our stock on the NYSE
Amex for the five days preceding the date our board of directors and stockholders approved the
issuance of the shares.
We reimburse Dr. Frost for Company-related use by Dr. Frost and our other executives of an
airplane owned by a company that is beneficially owned by Dr. Frost. We reimburse Dr. Frost in an
amount equal to the cost of a first class airline ticket between the travel cities for each
executive, including Dr. Frost, traveling on the airplane for Company-related business. We do not
reimburse Dr. Frost for personal use of the airplane by Dr. Frost or any other executive; nor do we
pay for any other fixed or variable operating costs of the airplane. For the fiscal year ending
December 31, 2008, we reimbursed Dr. Frost approximately $108,000 for Company-related travel by Dr.
Frost and other OPKO executives.
During the fiscal year ending December 31, 2008, we reimbursed SafeStitch Medical, Inc.
(SafeStitch) approximately $49,000, for time SafeStitchs personnel spent assisting us with the
implementation of certain quality and control standard operating procedures at our manufacturing
facility in Toronto, Ontario. Jane Hsiao, our Vice Chairman and Chief Technical Officer, serves as
chairman of the board of directors for SafeStitch; and Steven Rubin, our Executive Vice
President-Administration, and Richard Pfenniger, each of whom are members of our board of
directors, also serve on the board of directors of SafeStitch.
On September 10, 2008, in exchange for a $15.0 million cash investment in the Company, we
issued 13,513,514 shares of our common stock, par value $.01, to a group of investors which
included members of the Frost Group. The shares were issued at a price of $1.11 per share,
representing an approximately 40% discount to the 5 day average trading price of our stock on the
NYSE Amex. The shares issued in the private placement were restricted securities, subject to a two
year lockup, and no registration rights have been granted.
On September 19, 2007, we entered into an exclusive technology license agreement with Winston
Laboratories, Inc. (Winston). Under the terms of the license agreement, Winston granted us an
exclusive license to the proprietary rights of certain products in exchange for the payment of an
initial licensing fee, royalties, and payments on the occurrence of certain milestones. Subsequent
to our entering into the license agreement with Winston, on November 13, 2007, Winston issued
5,815,851 shares of its Series A Preferred Stock and warrants to purchase 4,092,636 shares of its
Series A Preferred Stock to a group of investors led by Dr. Frost, which also included Steven
Rubin, our Executive Vice President-Administration, and Rao Uppaluri, the Companys Senior Vice
President and Chief Financial Officer. In addition, effective the same day, Getting Ready
Corporation, entered into a definitive Merger Agreement and Plan of Reorganization with Winston,
now a wholly-owned subsidiary of Getting Ready Corporation. Getting Ready Corporation, now known
as Winston Pharmaceuticals, Inc., was a publicly held shell corporation of which approximately 42%
was owned, prior to the merger with Winston, by Dr. Frost, Messrs. Rubin and Uppaluri and Jane
Hsiao, our Vice Chairman and Chief Technical Officer (the Investors). Currently, the Investors
beneficially own approximately 30% of Winston Pharmaceuticals, Inc. and Mr. Uppaluri has served as
a member of Winstons board of directors since September 2008.
We intend to enter into an agreement to lease approximately 10,000 square feet of space in
Hialeah, Florida to house manufacturing and service operations for our ophthalmic instrumentation
business (the Hialeah Facility) from an entity controlled by Dr. Frost, our Chairman and Chief
Executive Officer, and Dr. Hsiao, our Vice Chairman and Chief Technical Officer. Pursuant to the
terms of the lease agreement, we anticipate paying gross rent of approximately $110,000 per year
for a one-year period which commenced February 1, 2009. From April 2008 through January 30, 2009,
we leased 20,000 square feet at the Hialeah Facility from a third party landlord pursuant to a
lease agreement which contained an option to purchase the facility. We initially elected to
exercise the option to purchase the Hialeah Facility in September 2008. Prior to closing, however,
we assigned the right to purchase the Hialeah Facility to the entity controlled by Drs. Frost and
Hsiao and lease back only a smaller portion of the facility as a result of several factors,
including our inability to obtain outside financing for the purchase, current business needs, the
reduced operating costs for the smaller space, and the minimization of risk and expense of
unutilized space.
13
Table of Contents
On February 23, 2009, we entered into a stock purchase agreement with Gamma Trust pursuant to
which the Gamma Trust agreed to make a $20.0 million investment in exchange for 20,000,000 shares
of our common stock, par value $.01, at $1.00 per share, representing an approximately 20% discount
to the average closing price of our common stock on the NYSE Amex for the five trading days
immediately preceding the effective date of Audit Committee and stockholder approval of the
transaction. The shares issued in the private placement were restricted securities, subject to a
two year lockup, and no registration rights have been granted.
On March 4, 2009, the Gamma Trust advanced $3.0 million to us under a Promissory Note we
issued to the Gamma Trust (the Note). The entire amount of this advance and all accrued interest
thereon is due and payable on the earlier of May 4, 2009 or such earlier date following the closing
of the previously disclosed Stock Purchase Agreement, dated February 23, 2009. The Note bears
interest at a rate equal to 11% per annum and may be prepaid in whole or in part without penalty or
premium. We repaid the Note in full in April 2009.
Our Policies Regarding Related Party Transactions
In April 2007, we adopted a written statement of policy with respect to related party
transactions, which is administered by our audit committee. Under our related party transaction
policy, a Related Party Transaction is any transaction, arrangement, or relationship between us
or any of our subsidiaries and a Related Person, not including any transactions involving less than
$60,000 when aggregated with all similar transactions, or transactions that have received
pre-approval of our audit committee. A Related Person is any of our executive officers,
directors or director nominees, any stockholder beneficially owning in excess of 5% of our stock or
securities exchangeable for our stock, any immediate family member of any of the foregoing persons,
and any firm, corporation, or other entity in which any of the foregoing persons is an executive
officer, a partner or principal or in a similar position, or in which such person has a 5% or
greater beneficial ownership interest in such entity.
Pursuant to our related party transaction policy, a Related Party Transaction may only be
consummated if:
| Our audit committee approves or ratifies such transaction in accordance with the terms of the Policy; or | ||
| the chair of our audit committee pre-approves or ratifies such transaction and the amount involved in the transaction is less than $100,000, provided that for the Related Party Transaction to continue it must be approved by our audit committee at its next regularly scheduled meeting. |
If advance approval of a Related Party Transaction is not feasible, then that Related Party
Transaction will be considered and, if our audit committee determines it to be appropriate,
ratified, at its next regularly scheduled meeting. If we decide to proceed with a Related Party
Transaction without advance approval, then the terms of such Related Party Transaction must permit
termination by us without further material obligation in the event our audit committee ratification
is not forthcoming at our audit committees next regularly scheduled meeting.
Transactions with related persons, though not classified as Related Party Transactions by our
related party transaction policy and thus not subject to its review and approval requirements, may
still need to be disclosed if required by the applicable securities laws, rules, and regulations.
14
Table of Contents
DIRECTOR COMPENSATION
Each non-employee director is entitled to receive an annual retainer of $10,000, payable in
quarterly installments, an option to acquire 40,000 shares of the Companys common stock upon
initial appointment to the Board and an option to acquire 20,000 shares each year thereafter on the
date of the Companys annual meeting of stockholders. The chairman of each committee of the Board
will also receive an additional annual retainer of $5,000, payable in quarterly installments.
The following table sets forth information with respect to compensation of non-employee
directors of the Company during fiscal year 2008.
Fiscal 2008 Director Compensation
Fees | Nonqualified | |||||||||||||||||||||||||||
Earned | Non-Equity | Deferred | ||||||||||||||||||||||||||
or Paid | Stock | Option | Incentive Plan | Compensation | All Other | |||||||||||||||||||||||
in Cash | Award | Awards | Compensation | Earnings | Compensation | Total | ||||||||||||||||||||||
Name | ($) | ($) | ($)(1) | ($) | ($) | ($) | ($) | |||||||||||||||||||||
Robert A. Baron |
15,000 | | 47,769 | | | | 62,769 | |||||||||||||||||||||
David A. Eichler (2) |
3,750 | | | | | | 3,750 | |||||||||||||||||||||
Thomas E. Beier |
10,000 | | 68,556 | | | | 78,556 | |||||||||||||||||||||
Michael Reich (3) |
10,000 | | 195,110 | | | | 205,110 | |||||||||||||||||||||
Richard A. Lerner, M.D. |
15,000 | | 39,839 | | | | 54,839 | |||||||||||||||||||||
Richard C. Pfenniger, Jr. |
15,000 | | 68,556 | | | | 83,556 | |||||||||||||||||||||
Pascal J. Goldschmidt,
M.D. |
10,000 | | 69,327 | | | | 79,327 | |||||||||||||||||||||
John A. Paganelli |
10,000 | | 47,769 | | | | 57,769 |
(1) | Reflects the dollar amounts recognized for financial statement reporting purposes for the year ended December 31, 2008, in accordance with Statement of Financial Accounting Standards No. 123R, or SFAS No. 123R, excluding the impact of estimated forfeitures related to service-based vesting conditions. Assumptions made in the calculation of these amounts are included in Note 8 to the Companys audited financial statements, included in the Companys Annual Report on Form 10-K filed with the SEC on March 16, 2009. The grant date fair value of the annual stock option award to acquire 20,000 shares granted during Fiscal 2008 to each of our non-employee directors and computed in accordance with FAS 123(R) was $0.97 per share. In addition, the fair value of the stock option award to acquire 40,000 shares granted to each of Messrs. Beier and Pfenniger upon their appointment to the Board in January 2008 was $1.51 per share. The table below sets forth the aggregate number of stock options of each non-employee director outstanding as of December 31, 2008: |
Name |
Stock Options | |||
Robert A. Baron |
115,000 | |||
David A. Eichler |
0 | |||
Thomas E. Beier |
60,000 | |||
Michael Reich |
111,894 | |||
Richard A. Lerner, M.D. |
60,000 | |||
Richard C. Pfenniger, Jr. |
60,000 | |||
Pascal J. Goldschmidt, M.D. |
60,000 | |||
John A. Paganelli |
115,000 |
(2) | On January 18, 2008, David Eichler resigned as a member of the Board of Directors. Amount was paid in 2008 for services to the Company in 2007. | |
(3) | On January 27, 2009, Michael Reich resigned as a member of the Board of Directors. |
15
Table of Contents
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our directors, executive officers and holders of
ten percent (10%) or more of our common stock (collectively, Reporting Persons) to file with the
SEC initial reports of ownership and reports of changes in ownership of our common stock and any
other equity securities. Based on a review of the copies of the reports furnished to us, the
Reporting Persons complied with all applicable Section 16(a) filing requirements except for (i) one
late Form 4 filing for Mr. Reich; and (ii) one late Form 3 filing and one late Form 4 filing for
Dr. Shams.
16
Table of Contents
EXECUTIVE COMPENSATION
Compensation Discussion and Analysis
Our compensation philosophy is to attract and retain talented and dedicated executives who
will work to achieve our desired business direction, strategy, and performance. The primary goals
of our compensation program for our Named Executive Officers are (i) to attract, motivate, and
retain talented executives with the skill sets and expertise we need to meet our scientific and
business objectives; (ii) to be competitive in the marketplace; (iii) to tie annual and long-term
cash and equity incentives to the achievement of specified performance objectives that will result
in increased stockholder value; and (iv) to be cost-effective. To achieve these goals, we have
formed a compensation committee that recommends executive compensation packages to our Board of
Directors. These packages are generally based on a mix of salary, discretionary bonus, and equity
awards. Although we have not adopted any formal guidelines for allocating total compensation
between equity compensation and cash compensation, we maintain compensation plans that tie a
substantial portion of our executives overall compensation to the achievement of corporate goals.
Benchmarking of Cash and Equity Compensation
Our compensation committee reviews executive compensation levels on an annual basis to ensure
they remain competitive in our industry. Data for this review is prepared and provided to the
compensation committee by our Vice President, Human Resources, with input from our Chief Executive
Officer, as well as other members of senior management. This data details relevant market rates
for executive base salaries, annual cash incentive, long-term incentive, and total compensation for
companies of similar size in our industry. The sources for this data for the previous fiscal year
included the Executive Compensation Survey, a survey of 67 biotech companies ranging in size from
less than $20 million in revenues with less than 150 employees to over $500 million in revenue with
over 1,000 employees. The data we used for our analysis focused on 24 companies with less than $20
million in revenues and less than 150 employees. We believe that criteria used by the Executive
Compensation Survey were effective in yielding a comprehensive survey group of companies, or peer
groups, comparable to the Company for the previous fiscal year. Utilizing the compiled
information, the compensation committee in 2008 reviewed the various components of executive
compensation to determine the base salary, annual cash incentive, long term incentive, and equity
compensation.
We may retain the services of third-party executive compensation specialists from time to time
in connection with the establishment of cash and equity compensation and related policies, although
we have not previously done so.
Elements of Compensation
We evaluate individual executive performance with a goal of setting compensation at levels the
Board of Directors and the compensation committee believe are comparable with executives in other
companies of similar size and stage of development. At the same time, our Board of Directors and
compensation committee takes into account our relative performance and our own strategic goals.
The primary elements of our compensation plans are base salary, discretionary annual bonus, and
equity compensation, each of which is described in greater detail below.
Base Salary. We establish and maintain competitive annual base salaries for our Named
Executive Officers by utilizing available resources, which include surveys as discussed above.
While base salaries are not primarily performance-based, we believe it is important to provide
adequate, fixed compensation to executives working in a highly volatile and competitive industry
such as ours. We provide fixed salary compensation to our Named Executive Officers based on their
responsibilities and individual experience, taking into account competitive market compensation
paid by other companies for similar positions within the pharmaceutical industry. Although it is
the general intent of the compensation committee to position base salaries at approximately the
competitive median of the Companys peer groups based on data reviewed, the base salaries for the
Companys Named Executive Officers in 2007 were below the median of our peer group. Because we are
a development stage company and have generated little revenue, we have tried to place an emphasis
on incentive forms of compensation, such as stock option grants. For 2008 and 2009, none of the
Named Executive Officers were granted increases in their base salaries.
17
Table of Contents
Discretionary Annual Bonus. In addition to base salaries, our compensation committee has the
authority to award discretionary annual bonuses to our Named Executive Officers based on corporate
and individual performance. Incentives, as a percent of salary, increase with executive rank so
that, as rank increases, a greater portion of total annual cash compensation is based on annual
corporate and individual performance. Furthermore, as an executives rank increases, a greater
percentage of that executives cash bonus is based on corporate performance, rather than individual
performance. Because we are a development stage company and generated little revenue in 2007 and
2008, the compensation committee determined not to award cash incentive bonuses in 2008 and 2009 and to
focus on other forms of compensation, such as stock options.
Equity Compensation. We believe that equity compensation should be a primary component of our
executive compensation program. Stock options are a critical element of our long-term incentive
strategy. The primary purpose of stock options is to provide Named Executive Officers and other
employees with a personal and financial interest in our success through stock ownership, thereby
aligning the interests of such persons with those of our stockholders. This broad-based program is
a vital element of our goal to empower and motivate outstanding long-term contributions by our
Named Executive Officers and other employees. The compensation committee believes that the value
of stock options will reflect our financial performance over the long-term. Under our employee
stock option program, options are granted at fair market value at the date of grant, and options
granted under the program become exercisable only after a vesting period. Consequently, employees
benefit from stock options only if the market value of our common stock increases over time. With
respect to these stock options, we recognize compensation expense based on the Statement of
Financial Accounting Standard 123R, Share-Based Payments (SFAS 123R). The compensation
committee typically grants stock options to our Named Executive Officers under our 2007 Equity
Incentive Plan. For all executives, other than the Chief Executive Officer, the compensation
committee considers the recommendations of our Chief Executive Officer based on his subjective
assessment of their performance. We have not granted any restricted stock or restricted stock
awards pursuant to our equity benefit plans. However, our compensation committee, in its
discretion, may in the future elect to make such grants to our Named Executive Officers if it deems
it advisable.
Employment Agreements. We have not entered into an employment agreement with any of our
current executive officers.
Severance and Change-in-Control Benefits. None of our current executive officers are entitled
to severance or change of control benefits; provided however, that the OPKO Health, Inc. 2007
Equity Incentive Plan provides for certain accelerated vesting upon change in control events.
401(k) Profit Sharing Plan. We have adopted a tax-qualified 401(k) Profit Sharing Plan (the
401(k) Plan) covering all qualified employees. The effective date of the 401(k) Plan is January
2008. Participants may elect a salary reduction of at least 1% as a contribution to the 401(k)
Plan, up to the statutorily prescribed annual limit for tax-deferred contributions ($15,500 for
employees under age 50 and an additional $5,000 for employees 50 and above in 2008). In 2008, the
Company adopted the Roth contribution for employee elections. The 401(k) Plan permits employer
matching of up to 4% of a participants salary up to the statutory limits. In 2008, we elected a
safe harbor contribution at 4% of annual compensation. All of our safe harbor contributions are
immediately vested.
Other Compensation. All of our Named Executive Officers have standard benefits that are
offered to all full-time, exempt employees. These standard benefits include health, dental and
life insurance, and short and long term disability. We intend to continue to maintain the current
benefits and perquisites for our Named Executive Officers; however, our compensation committee, in
its discretion, may in the future revise, amend, or add to the benefits and perquisites of any
Named Executive Officer if it deems it advisable.
Section 162(m) of the Internal Revenue Code
Section 162(m) of the Internal Revenue Code generally does not allow a deduction for annual
compensation in excess of $1,000,000 paid to our executive officers. This limitation on
deductibility does not apply to certain compensation, including performance based compensation
under a plan approved by our stockholders. It is expected that equity grants under our 2007 Equity
Incentive Plan will qualify for the performance-based exceptions from the Section 162(m)
limitations. Our policy is generally to preserve the federal income tax deductibility of
compensation and to qualify eligible compensation for the performance-based exception in order for
18
Table of Contents
compensation not to be subject to the limitation on deductibility imposed by Section 162(m) of the
Internal Revenue Code. We may, however, approve compensation that may not be deductible if we
determine that the compensation is in our best interests as well as the best interests of our
stockholders.
19
Table of Contents
COMPENSATION COMMITTEE REPORT
The compensation committee of our Board has submitted the following report for inclusion in
this proxy statement.
The compensation committee has reviewed and discussed the Compensation Discussion and Analysis
contained in this proxy statement with management. Based on its review and discussions with
management with respect to the Compensation Discussion and Analysis, the compensation committee
recommended to the Board that the Compensation Discussion and Analysis be included in this proxy
statement on Schedule 14A for filing with the Securities and Exchange Commission.
Compensation Committee
Richard A. Lerner, M.D., Chairman
Thomas E. Beier
Pascal J. Goldschmidt, M.D.
Thomas E. Beier
Pascal J. Goldschmidt, M.D.
The compensation committee report above shall not be deemed to be soliciting material or to be
filed with the Securities and Exchange Commission, nor shall such information be incorporated by
reference into any future filing under the Securities Act of 1933 or the Securities Exchange Act of
1934, each as amended, except to the extent that we specifically incorporate it by reference into
such filing.
20
Table of Contents
Summary Compensation Table
The following table sets forth information regarding compensation earned in or with respect to
fiscal 2008 and 2007 by:
| Our Chief Executive Officer during fiscal 2008; | ||
| Our Principal Financial Officer during fiscal 2008; and | ||
| Our only three executive officers (other than individuals serving as our Chief Executive Officer or our Principal Financial Officer) who were serving as executive officers at the end of the last completed fiscal year. |
We refer to these officers collectively as our Named Executive Officers.
Option | All Other | |||||||||||||||||||||||||||
Stock Award(s) | Award(s) | Compensation | ||||||||||||||||||||||||||
Name and Principal Position | Year | Salary ($) | Bonus ($) | ($) | ($) (2) | ($) (3) | Total ($) | |||||||||||||||||||||
Phillip Frost, M.D. (1) |
2008 | 325,000 | 809,899 | 9,200 | 1,144,099 | |||||||||||||||||||||||
Chief Executive Officer |
2007 | 208,332 | | | 503,517 | 133,333 | 845,182 | |||||||||||||||||||||
Jane H. Hsiao, Ph.D. (1) |
2008 | 300,000 | 536,449 | 9,200 | 845,649 | |||||||||||||||||||||||
Chief Technical Officer |
2007 | 192,307 | | | 327,286 | 7,692 | 527,286 | |||||||||||||||||||||
Steven D. Rubin (1) |
2008 | 300,000 | 414,054 | 9,200 | 723,254 | |||||||||||||||||||||||
Executive Vice
President-Administration |
2007 | 192,307 | | | 251,758 | 7,692 | 451,278 | |||||||||||||||||||||
Rao Uppaluri, Ph.D. (1) |
2008 | 275,000 | 333,974 | 9,200 | 618,174 | |||||||||||||||||||||||
Senior Vice President and |
2007 | 176,284 | | | 201,407 | 7,051 | 384,743 | |||||||||||||||||||||
Chief Financial Officer |
||||||||||||||||||||||||||||
Naveed Shams, M.D., Ph.D. (1) |
2008 | 259,135 | 71,430 | 25,830 | 356,395 | |||||||||||||||||||||||
Senior Vice President- |
2007 | | | | | | | |||||||||||||||||||||
Research & Development
and Chief Medical Officer |
(1) | Dr. Frost became our Chief Executive Officer on March 27, 2007. Dr. Hsiao was appointed as Chief Technical Officer in May 2007. Mr. Rubin and Dr. Uppaluri were appointed as Executive Vice President, Administration and Senior Vice President and Chief Financial Officer, respectively, in May 2007. Dr. Shams joined the Company on January 14, 2008. None of our current executive officers received any compensation from the Company prior to 2007. | |
(2) | Reflects the dollar amounts recognized for financial statement reporting purposes for the year ended December 31, 2008, in accordance with Statement of Financial Accounting Standards No. 123R, or SFAS No. 123R, excluding the impact of estimated forfeitures related to service-based vesting conditions. Assumptions made in the calculation of these amounts are included in Note 8 to the Companys audited financial statements, included in the Companys Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2009. | |
(3) | Includes $125,000 for a Hart-Scott-Rodino Antitrust Improvements Act filing fee paid on behalf of Dr. Frost in June 2007; (ii) contributions made by the Company under its 401(k) Plan during fiscal 2007 in the amount of $8,333 on behalf of Dr. Frost, $7,692 on behalf of each of Dr. Hsiao and Mr. Rubin and $7,051 on behalf of Dr. Uppaluri; (iii) contributions made by the Company under its 401(k) Plan during fiscal 2008 in the amount of $9,200 for each of Drs. Frost, Hsiao, Shams and Uppaluri and Mr. Rubin; and (iv) temporary housing costs (including tax gross ups) for Dr. Shams in connection with his joining the Company in 2008. |
21
Table of Contents
Grants of Plan-Based Awards in 2008
The following table presents information concerning grants of plan-based awards to each of the
Named Executive Officers and certain other persons during the year ended December 31, 2008. The
exercise price per share of each option granted to our Named Executive Officers during 2008 was
equal to the fair market value of our common stock, as determined by our compensation committee on
the date of the grant.
Grant Date | ||||||||||||||
Number of Securities | Exercise Price | Fair Value of | ||||||||||||
Name | Grant Date | Underlying Options | Per Share($) | Option Awards ($) | ||||||||||
Phillip Frost, M.D. (1)
|
4/28/08 | 300,000 | 1.65 | 291,330 | ||||||||||
Jane H. Hsiao, Ph.D. (1)
|
4/28/08 | 250,000 | 1.65 | 242,775 | ||||||||||
Steven D Rubin (1)
|
4/28/08 | 200,000 | 1.65 | 194,220 | ||||||||||
Rao Uppaluri, Ph.D. (1)
|
4/28/08 | 175,000 | 1.65 | 169,943 | ||||||||||
Naveed Shams, M.D., Ph.D. (2)
|
1/14/08 | 150,000 | 3.24 | 285,720 |
(1) | Options vest in four equal annual tranches beginning April 28, 2009 and will expire on April 27, 2015. | |
(2) | Options vest in four equal annual tranches beginning January 14, 2009 and will expire on January 13, 2015. |
Outstanding Equity Awards at Fiscal Year-End
The following table sets forth information as of December 31, 2008 with respect to equity
awards outstanding at December 31, 2008.
Option Awards | Stock Awards | |||||||||||||||||||||||
Number of | Number of | |||||||||||||||||||||||
Securities | Securities | Number of | Market Value of | |||||||||||||||||||||
Underlying | Underlying | Shares or Units | Shares or | |||||||||||||||||||||
Unexercised | Unexercised | Option | Option | of Stock That | Units of Stock | |||||||||||||||||||
Options | Options | Exercise | Expiration | Have Not | That Have Not | |||||||||||||||||||
Name | (#) Exercisable | (#) Unexercisable | Price ($) | Date | Vested (#) | Vested ($) | ||||||||||||||||||
Phillip Frost, M.D. |
250,000 | (1) | 750,000 | (1) | 4.88 | 5/2/14 | | | ||||||||||||||||
| 300,000 | (2) | 1.65 | 4/27/15 | | | ||||||||||||||||||
Jane H. Hsiao, Ph.D. |
162,500 | (1) | 487,500 | (1) | 4.88 | 5/2/14 | | | ||||||||||||||||
| 250,000 | (2) | 1.65 | 4/27/15 | | | ||||||||||||||||||
Steven D. Rubin |
125,000 | (1) | 375,000 | (1) | 4.88 | 5/2/14 | | | ||||||||||||||||
| 200,000 | (2) | 1.65 | 4/27/15 | | | ||||||||||||||||||
Rao Uppaluri, Ph.D. |
100,000 | (1) | 300,000 | (1) | 4.88 | 5/2/14 | | | ||||||||||||||||
| 175,000 | (2) | 1.65 | 4/27/15 | | | ||||||||||||||||||
Naveed Shams, M.D.,
Ph.D. |
| 150,000 | (3) | 3.24 | 1/13/15 | | |
(1) | Options were issued on May 3, 2007 and vest in four equal annual tranches beginning on May 3, 2008. | |
(2) | Options were issued on April 28, 2008 and vest in four equal annual tranches beginning April 28, 2009. | |
(3) | Options were issued on January 14, 2008 and vest in four equal annual tranches beginning on January 14, 2009 |
Option Exercises during Fiscal 2008
None of our Named Executive Officers exercised stock options during fiscal 2008.
Pension Benefits
None of our Named Executive Officers is covered by a pension plan or other similar benefit
plan that provides for payments or other benefits at, following, or in connection with retirement.
22
Table of Contents
Employment Agreements and Change in Control Arrangements
None of our Named Executive Officers are entitled to severance or change of control benefits;
provided however, that the OPKO Health, Inc. 2007 Equity Incentive Plan provides for certain
accelerated vesting upon change in control events.
Fiscal Year-End Equity Compensation Plan Information
The following table sets forth aggregated information concerning our equity compensation plans
outstanding at December 31, 2008.
Number of | ||||||||||||
Securities to be | Number of Securities | |||||||||||
Issued upon | Remaining Available | |||||||||||
Exercise of | for Future Issuance | |||||||||||
Outstanding | Under Equity | |||||||||||
Options, Warrants | Weighted-Average | Compensation Plans | ||||||||||
and Rights | Exercise Price of | (excluding shares | ||||||||||
Outstanding | Outstanding Options, | reflected in | ||||||||||
Plan Category | at FY End (#) | Warrants and Rights | the 1st column) | |||||||||
Equity Compensation
Plans Approved by
Stockholders |
11,977,437 | $ | 2.08 | 17,002,650 | ||||||||
Equity Compensation
Plans Not Approved
by Stockholders |
| | | |||||||||
Total |
11,977,437 | $ | 2.08 | 17,002,650 | ||||||||
23
Table of Contents
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The audit committee has selected Ernst & Young LLP (Ernst & Young), as the Companys
independent registered public accounting firm to audit our financial statements for fiscal 2009 and to express an opinion on the effectiveness of our
internal control over financial reporting as of December 31, 2009.
We expect that a representative of Ernst & Young will attend the Annual Meeting, will have an
opportunity to make a statement if he or she desires to do so, and will be available to respond to
appropriate questions.
On April 9, 2007, the Board of Directors of the Company approved the decision to dismiss
Rotenberg & Co., LLP (Rotenberg & Co.) and to engage Ernst & Young as the Companys independent
registered public accounting firm to audit our financial statements for the fiscal year ended
December 31, 2007. Rotenberg & Co. served as our independent auditors for 2006. Our stockholders,
acting by majority written consent, ratified this appointment of Ernst & Young as the Companys
independent registered public accounting firm effective June 5, 2007.
The reports of Rotenberg & Co. for the fiscal years ended December 31, 2006 and 2005 did not
contain any adverse opinion or disclaimer of opinion and were not modified or qualified as to
uncertainty, audit scope, or accounting principles. From September 23, 2005 through the end of the
fiscal year ended December 31, 2006, there were no disagreements with Rotenberg & Co. on any matter
of accounting principles or practices, financial statement disclosure, or auditing scope or
procedure, which disagreements, if not resolved to the satisfaction of Rotenberg & Co., would have
caused Rotenberg & Co. to make reference to the subject matter of the disagreements in connection
with its report and there were no reportable events as defined in Item 304(a)(1)(v) of Regulation
S-K.
On April 9, 2007, the Company requested that Rotenberg & Co. furnish it with a letter
addressed to the Securities and Exchange Commission stating whether or not it agrees with the above
statements. A copy of such letter, dated April 11, 2007, was filed as an exhibit to a Current
Report on Form 8-K filed by the Company on April 13, 2007.
During the fiscal years ended December 31, 2005 and 2006 and from January 1, 2007 through
April 9, 2007, neither the Company nor anyone acting on its behalf consulted Ernst & Young
regarding (1) either the application of accounting principles to a specified transaction, either
completed or proposed, or the type of audit opinion that might be rendered on the Companys
consolidated financial statements or (2) any matter that was either the subject of a disagreement
with Rotenberg & Co. on accounting principles or practices, financial statement disclosure, or
auditing scope or procedures, which, if not resolved to the satisfaction of Rotenberg & Co., would
have caused Rotenberg & Co. to make reference to the matter in its report, or a reportable event as
defined in Item 304(a)(1)(v) of Regulation S-K of the Securities and Exchange Commission. On April
11, 2007, the Company provided a copy of the foregoing disclosure to Ernst & Young and provided
Ernst & Young with an opportunity to furnish a letter addressed to the Securities and Exchange
Commission containing any new information, clarification of the Companys expression of its views,
or the respects in which it does not agree with the statements made by the Company. Ernst & Young
advised the Company that it reviewed the foregoing disclosures and had no basis on which to submit
such a letter addressed to the Securities and Exchange Commission in response to Item 304 of SEC
Regulation S-K.
The following table presents fees for professional audit services provided by Ernst & Young
for the audit of our annual financial statements and internal control over financial reporting for fiscal 2008 and the audit of our annual financial statements for fiscal 2007 (in
thousands):
FY 2008 | FY 2007 | |||||||
Audit Fees |
$ | 474,375 | $ | 327,043 | ||||
Audit Related Fees |
| | ||||||
Tax Fees |
| | ||||||
All Other Fees |
| | ||||||
Total |
$ | 474,375 | $ | 327,043 | ||||
Audit Fees include fees for services rendered for the audit of our annual consolidated
financial statements (2007 and 2008), the audit of internal control over financial reporting (2008), the review of
financial statements included in our quarterly reports on Form 10-Q, and consents and other
services normally provided in connection with statutory and regulatory filings or engagements for
those fiscal years.
24
Table of Contents
Audit-Related Fees would principally include fees incurred for due diligence in connection with
potential transactions and accounting consultations. There were no audit-related fees incurred during 2007 and 2008.
Tax Fees would include fees for services rendered for tax compliance, tax advice, and tax
planning. There were no tax fees incurred with Ernst & Young in 2007 and 2008.
All Other Fees would include fees for all other services rendered to us that do not constitute
Audit Fees, Audit-Related Fees, or Tax Fees. There were no such fees incurred with Ernst & Young in 2007 and 2008.
Audit Committee Policy for Pre-approval of Independent Auditor Services
The audit committee of the Board of Directors is required to pre-approve all audit and non-audit
services provided by the Companys independent auditors in order to assure that the provision of
such services does not impair the auditors independence. The audit committee has established a
policy regarding pre-approval of permissible audit, audit-related, and other services provided by
the independent auditors, which services are periodically reviewed and revised by the audit
committee. Unless a type of service has received general pre-approval under the policy, the
service will require specific approval by the audit committee. The policy also includes
pre-approved fee levels for specified services and any proposed service exceeding the established
fee level must be specifically approved by the committee. All audit and permitted non-audit
services and all fees associated with such services performed by our independent registered public
accounting firm in fiscal 2008 and 2007 were approved by the full Audit Committee consistent with the policy
described above.
25
Table of Contents
AUDIT COMMITTEE REPORT
The following Audit Committee Report shall not be deemed to be soliciting material or to be
filed with the SEC or incorporated by reference in any other filing by us under the Securities
Act of 1933 or Securities Exchange Act of 1934.
The members of the audit committee of the Board are Messrs. Pfenniger, Baron, and Beier. The
primary purpose of the audit committee is to assist the Board in its general oversight of the
Companys accounting and financial reporting processes. The audit committees functions are more
fully described in its charter, which the Board has adopted. The audit committee reviews and
reassesses the adequacy of its charter on an annual basis. The Board annually reviews the NYSE
Amex listing standards definition of independence for audit committee members and has determined
that each member of the audit committee is independent under that standard.
Management is responsible for the preparation, presentation, and integrity of the Companys
financial statements, accounting and financial reporting principles, and internal controls and
procedures designed to ensure compliance with accounting standards, applicable laws, and
regulations.
The Companys independent registered public accounting firm, Ernst & Young LLP, is responsible
for performing an independent annual audit of the Companys consolidated financial statements and
expressing an opinion on both the conformity of those financial statements with United States
generally accepted accounting principles and on the effectiveness of our internal control over
financial reporting. The audit committees policy is that all services rendered by the Companys
independent auditor are either specifically approved or pre-approved and are monitored both as to
spending level and work content to maintain the appropriate objectivity and independence of the
independent auditor. The audit committees policy provides that the audit committee has the
ultimate authority to approve all audit engagement fees and terms and that the audit committee
shall review, evaluate, and approve the engagement proposal of the independent auditor.
In conjunction with its activities during fiscal 2008, the audit committee reviewed and
discussed our interim results and the annual integrated audit of our financial statements and
internal control over financial reporting with the Companys independent registered public
accounting firm with and without management present, and with management. The members of the audit
committee discussed the quarterly review procedures and annual audit procedures performed by
the independent registered public accounting firm in connection with the quarterly unaudited and
annual audited financial statements and discussed and agreed upon procedures related to the audit of internal control over financial reporting with management
of the Company and its independent registered public accounting firm. The members of the audit
committee also discussed with the Companys independent registered public accounting firm the
matters required to be discussed by the Statement on Auditing Standards No. 61, as amended. In addition, the audit committee received from
the Companys independent registered public accounting firm the written disclosures and the letter
required by the Public Company Accounting Oversight Board regarding the independent registered
public accounting firms communications with the audit committee concerning independence and has
discussed its independence with the independent registered public accounting firm. Based on the
foregoing reviews and discussions, the audit committee recommended to the Board, and the Board
approved, that the fiscal 2008 annual audited financial statements be included in the Companys
Annual Report on Form 10-K for fiscal 2008 for filing with the SEC.
Audit Committee
Richard C. Pfenniger, Jr., Chairman
Robert A. Baron
Thomas E. Beier
Richard C. Pfenniger, Jr., Chairman
Robert A. Baron
Thomas E. Beier
26
Table of Contents
OTHER INFORMATION
Deadlines for Stockholder Proposals and Nominations for the 2010 Annual Meeting
Pursuant to Rule 14a-8 under the Exchange Act, our stockholders may present proper proposals
for inclusion in our proxy statement and form of proxy and for consideration at the next annual
meeting by submitting their proposals to us in a timely manner. Any stockholder of the Company who
wishes to present a proposal for inclusion in the proxy statement and form of proxy for action at
the 2010 annual meeting of stockholders (the 2010 Annual Meeting) must comply with our Amended
and Restated Bylaws and the rules and regulations of the SEC, each as then in effect. Such
proposals must be mailed to us at our offices at 4400 Biscayne Blvd., Miami, Florida 33137,
attention: Secretary. Under the rules of the SEC, any stockholder proposal intended to be
presented at the 2010 Annual Meeting must be received no later than December 31, 2009 in order to
be considered for inclusion in our proxy statement and form of proxy relating to such meeting. If
a stockholder notifies us of an intent to present a proposal at the 2010 Annual Meeting at any time
after March 16, 2010 (and for any reason the proposal is voted on at that meeting), it will be
considered untimely and our proxy holders will have the right to exercise discretionary voting
authority with respect to the proposal, if presented at the meeting, without including information
regarding the proposal in our proxy materials.
Expenses of Solicitation
We will bear the cost of this proxy solicitation. In addition to the use of the mails, some
of our regular employees, without additional remuneration, may solicit proxies personally or by
telephone or facsimile. We will reimburse brokers, dealers, banks, and other custodians, nominees,
and fiduciaries for their reasonable expenses in forwarding solicitation materials to beneficial
owners of our common stock.
Other Business
As of the date of this proxy statement, the Board knows of no business to be presented at the
Annual Meeting other than as set forth in this proxy statement. If other matters properly come
before the Annual Meeting, or any of its adjournments, the persons named as proxies will vote on
such matters in their discretion.
27
Table of Contents
PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR
BLACK INK AS SHOWN HERE [X]
1. Election of ten directors.
NOMINEES:
Phillip Frost, M.D.
Jane H. Hsiao, Ph.D.
Steven D. Rubin
Robert A. Baron
Thomas E. Beier
Pascal J. Goldschmidt, M.D.
Richard A. Lerner, M.D.
John A. Paganelli
Richard C. Pfenniger, Jr.
Alice Lin-Tsing Yu, M.D., Ph.D.
NOMINEES:
Phillip Frost, M.D.
Jane H. Hsiao, Ph.D.
Steven D. Rubin
Robert A. Baron
Thomas E. Beier
Pascal J. Goldschmidt, M.D.
Richard A. Lerner, M.D.
John A. Paganelli
Richard C. Pfenniger, Jr.
Alice Lin-Tsing Yu, M.D., Ph.D.
o | FOR ALL NOMINEES | |
o |
WITHHOLD AUTHORITY FOR ALL NOMINEES |
|
o |
FOR ALL EXCEPT (See instructions below) |
INSTRUCTION: To withhold authority to vote
for any individual nominee(s), mark FOR ALL
EXCEPT and write the nominees name(s)
below.
To change the address on your account, please
check the box at right and indicate your new
address in the address space above. Please
note that changes to the registered name(s)
on the account may not be submitted via this
method. o
2. | In their discretion, the proxy holders are authorized to vote upon such other matters as may properly come before the meeting or any postponement or adjournment thereof. |
THIS PROXY WHEN PROPERLY EXECUTED
WILL BE VOTED IN THE MANNER
DIRECTED HEREIN BY THE UNDERSIGNED.
IF NO DIRECTION IS MADE, THIS PROXY
WILL BE VOTED FOR ELECTION OF THE
DIRECTORS NAMED IN PROPOSAL 1.
PLEASE MARK, SIGN, DATE AND RETURN
THE PROXY CARD PROMPTLY USING THE
ENCLOSED ENVELOPE.
|
The undersigned acknowledges receipt of the accompanying Notice of Annual Meeting of
Stockholders and Proxy Statement for the June 10, 2009 meeting.
Signature of Shareholder Date:
Signature of Shareholder Date:
NOTE: Please sign exactly as your name or names appear on this Proxy. When shares are held jointly,
each stockholder should sign. When signing as executor, administrator, attorney, trustee or
guardian, please give full title as such. If the signer is a corporation, please sign full
corporate name by duly authorized officer, giving full title as such. If signer is a partnership,
please sign in partnership name by authorized person.
Table of Contents
PROXY
OPKO HEALTH, INC.
4400 Biscayne Blvd., Suite 1180
Miami, Florida 33137
4400 Biscayne Blvd., Suite 1180
Miami, Florida 33137
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
ANNUAL MEETING OF STOCKHOLDERS JUNE 10, 2009
The undersigned hereby appoints Rao Uppaluri and Steven Rubin, and each of them
severally, as proxies of the undersigned, each with full power to appoint his
substitute, to represent the undersigned at the Annual Meeting of Stockholders
of OPKO Health, Inc. (the Company) to be held on June 10, 2009, and at any
adjournments thereof, and to vote thereat all shares of common stock and Series A
Preferred Stock of the Company held of record by the undersigned at the close
of business on April 22, 2009 in accordance with the instructions set forth on
this proxy card and, in their discretion, to vote such shares on any other
business as may properly come before the meeting and on matters incident to the
conduct of the meeting. Any proxy heretofore given by the undersigned with
respect to such stock is hereby revoked.
PLEASE MARK, DATE AND SIGN THIS PROXY ON THE REVERSE SIDE AND RETURN IT IN THE
ENCLOSED ENVELOPE
ENCLOSED ENVELOPE